MHRA - Medicines and Healthcare products Regulatory Agency
MHRA - Medicines and Healthcare products Regulatory Agency
04/29/2024 | Press release | Distributed by Public on 04/29/2024 09:07
Finasteride: review of safety data and expert advice on management of risks
Research and analysis
Finasteride: review of safety data and expert advice on management of risks
Public Assessment Report of review of Finasteride safety data and expert advice on management of risks.
From:Medicines and Healthcare products Regulatory AgencyPublished29 April 2024
Get emails about this page
Documents
Finasteride: review of safety data and expert advice on management of risks
PDF, 541 KB, 35 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
This report presents the review of the safety data by the MHRA in 2023, the advice of the PEAG and the steps that the MHRA are taking to implement new safety measures with the support of patients and experts.
Published 29 April 2024
Get emails about this page
Print this page